Back to Search Start Over

Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression

Authors :
Pedro C. Lara
J.I. Rodríguez-Melcón
Palmira Foro-Arnalot
Estefanía Herrera-Ramos
Pablo Fernández-Gonzalo
José Francisco Suárez-Novo
Ferran Guedea
Montse Ferrer
Manel Castells-Esteve
Maria Jesus Alvarez-Cubero
Jose Manuel Cozar
Carlos Rodríguez-Gallego
Gemma Sancho-Pardo
Belén De-Paula-Carranza
Luis Alberto Henríquez-Hernández
María José Ortiz-Gordillo
A. Valenciano
Jordi Craven-Bartle
Patricia Cabrera-Roldán
Universitat de Barcelona
Source :
Dipòsit Digital de la UB, Universidad de Barcelona, Digibug. Repositorio Institucional de la Universidad de Granada, instname, Recercat. Dipósit de la Recerca de Catalunya, BMC Medical Genetics
Publication Year :
2014
Publisher :
BioMed Central, 2014.

Abstract

Background Besides serum levels of PSA, there is a lack of prostate cancer specific biomarkers. It is need to develop new biological markers associated with the tumor behavior which would be valuable to better individualize treatment. The aim of this study was to elucidate the relationship between single nucleotide polymorphisms (SNPs) in genes involved in DNA repair and prostate cancer progression.<br />Methods A total of 494 prostate cancer patients from a Spanish multicenter study were genotyped for 10 SNPs in XRCC1, ERCC2, ERCC1, LIG4, ATM and TP53 genes. The SNP genotyping was made in a Biotrove OpenArray® NT Cycler. Clinical tumor stage, diagnostic PSA serum levels, and Gleason score at diagnosis were obtained for all participants. Genotypic and allelic frequencies were determined using the web-based environment SNPator.<br />Results SNPs rs11615 (ERCC1) and rs17503908 (ATM) appeared as risk factors for prostate cancer aggressiveness. Patients wild homozygous for these SNPs (AA and TT, respectively) were at higher risk for developing cT2b – cT4 (OR = 2.21 (confidence interval (CI) 95% 1.47 – 3.31), p<br />Conclusions Genetic variants at DNA repair genes are associated with prostate cancer progression, and would be taken into account when assessing the malignancy of prostate cancer.<br />This work was subsidized by a grant from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad from Spain), ID: PI12/01867. Almudena Valenciano has a grant from the Instituto Canario de Investigación del Cáncer (ICIC).

Details

Database :
OpenAIRE
Journal :
Dipòsit Digital de la UB, Universidad de Barcelona, Digibug. Repositorio Institucional de la Universidad de Granada, instname, Recercat. Dipósit de la Recerca de Catalunya, BMC Medical Genetics
Accession number :
edsair.doi.dedup.....a4b97c4c7898c0d4848504cf66a86973